Osteoporosis
📧 Sign up to get email alerts when something new happens for Osteoporosis.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2020-05-15EMA Withdrawn: Protelos (strontium ranelate) — Les Laboratoires Servier
The EMA withdrew Protelos (strontium ranelate) from the market for osteoporosis, postmenopausal indications.
-
FDA approval · 2020-04-29FDA Approved: RECLAST — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for RECLAST (zoledronic acid) filed by Sandoz Inc.
-
CLINICAL_TRIALS trial_result · 2020-04-14Clinical Trial Update: Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy [Phase 2]
Phase 2 clinical trial evaluating Traditional Chinese Medicine as a preventive method for osteoporosis induced by adjuvant endocrine therapy…
-
FDA approval · 2020-04-06FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for teriparatide submitted by Prasco Laboratories under NDA 021318.
-
CLINICAL_TRIALS trial_result · 2020-04-02Clinical Trial Update: Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial [Phase 3]
Phase 3 clinical trial evaluating bone mineral density in postmenopausal women with primary breast cancer receiving treatment; completed stu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-03-24Clinical Trial Update: Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries [Phase 2]
Phase 2 trial evaluating zoledronate versus observation for maintaining bone mineral density in patients undergoing surgery to remove both o…
-
CLINICAL_TRIALS trial_result · 2020-03-20Clinical Trial Update: Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD [Phase 2]
Phase 2 clinical trial evaluating bone mineral density changes and safety of rhBMP-2/CPM in subjects with decreased bone mineral density (os…
-
FDA approval · 2020-02-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for Zoledronic acid from Dr. Reddy's Laboratories Limited, authorizing a generic product through…
-
FDA approval · 2020-02-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for zoledronic acid submitted by BluePoint Laboratories (ANDA205279).
-
CLINICAL_TRIALS trial_result · 2020-02-12Clinical Trial Update: Denosumab Versus Bisphosphonates (Alendronate) in GIOP [Phase 4]
Phase 4 trial comparing denosumab to alendronate in osteoporosis has completed.
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI [Phase 2]
Phase 2 trial update on neridronate (Nerixia) for osteoporosis in patients with thalassemia major/intermedia showing efficacy and safety res…
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults [NA]
A completed clinical trial assessing the effects of potassium bicarbonate supplementation on bone and muscle health in older adults.
-
CLINICAL_TRIALS trial_result · 2020-01-31Clinical Trial Update: Efficacy And Security Of Annual And Biennial Zoledronic Acid For Osteoporosis Treatment In An HIV-Infected Patients' Cohort [Phase 4]
Phase 4 trial update evaluating efficacy and safety of annual and biennial zoledronic acid for osteoporosis in HIV-infected patients.
-
FDA approval · 2019-12-20FDA Approved: EVENITY — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for Evenity (romosozumab-aqqg) from Amgen, reflecting regulatory approval based on the supplemental …
-
FDA approval · 2019-12-17FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for Apotex Corp. to market a generic ibandronate sodium product.
-
CLINICAL_TRIALS trial_result · 2019-12-12Clinical Trial Update: Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis [Phase 3]
Phase 3 trial comparing denosumab to zoledronic acid in thalassemia-induced osteoporosis was terminated.
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: Dissemination of a Theory-Based Bone Health Program in Online [NA]
Completed clinical trial evaluating a theory-based bone health program delivered online for osteoporosis and related health behaviors; resul…
-
FDA approval · 2019-10-04FDA Approved: TERIPARATIDE — Original Application (Alvogen, Inc.)
The FDA approved the original application for teriparatide from Alvogen, enabling its use for osteoporosis treatment.
-
FDA approval · 2019-10-03FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Teriparatide submitted by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2019-09-20Clinical Trial Update: 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids [Phase 3]
Open-label extension trial update for zoledronic acid given twice yearly in osteoporotic children treated with glucocorticoids; completed ph…
-
CLINICAL_TRIALS trial_result · 2019-09-18Clinical Trial Update: A Study on the Impact of Calcium on Woman's Vascular Health [Phase 4]
Phase 4 trial assessing the impact of calcium on vascular health in women, completed.
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: Phase 2a Study on Intravenous Infusion of Autologous Osteoblastic Cells in Severe Osteoporosis [Phase 2]
Phase 2a study evaluating intravenous infusion of autologous osteoblastic cells in patients with severe osteoporosis has completed.
-
CLINICAL_TRIALS trial_result · 2019-08-26Clinical Trial Update: Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis [Phase 2]
Phase 2 trial comparing denosumab to placebo in patients with thalassemia major and osteoporosis has completed.
-
FDA approval · 2019-08-23FDA Approved: RALOXIFENE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic raloxifene hydrochloride product from Aurobindo Pharma Limited.
-
FDA approval · 2019-08-19FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for alendronate sodium by Hikma Pharmaceuticals USA Inc.